Michael Vlemmix is an Equity Analyst at KBC Securities. Mr. Vlemmix joined the research team of KBC Securities in 2016 to focus on the biotech/health care sector. He was active for there years in the startup of a medical devices spinoff company of the University of Antwerp. He graduated as a Bioengineer at the University of Ghent and Antwerp, specialized in cell and gene biotechnology and obtained an additional Master in Management at the Antwerp Management School.
Small-to-Midcap Biotech Companies Expected to Regain Levels
March 10, 2017
